Alendronate Pt IV Prodrug Amphiphile for Enhanced Chemotherapy Targeting and Bone Destruction Inhibition in Osteosarcoma.

Autor: Sun K; Department of Pharmaceutics, School of Pharmacy, Qingdao University, Qingdao, 266021, China., Yuan L; Department of Pharmaceutics, School of Pharmacy, Qingdao University, Qingdao, 266021, China., Chen S; School of Medicine and Pharmacy, Ocean University of China, Qingdao, 266003, China., Sun Y; Department of Pharmaceutics, School of Pharmacy, Qingdao University, Qingdao, 266021, China., Wei D; Department of Pharmaceutics, School of Pharmacy, Qingdao University, Qingdao, 266021, China.
Jazyk: angličtina
Zdroj: Advanced healthcare materials [Adv Healthc Mater] 2024 Mar; Vol. 13 (7), pp. e2302746. Date of Electronic Publication: 2023 Nov 28.
DOI: 10.1002/adhm.202302746
Abstrakt: Chemotherapy remains the primary treatment method for osteosarcoma after surgery. However, the lack of selectivity of chemotherapy for osteosarcoma leads to unpredictable therapeutic effects, undesirable side effects, and drug resistance. A platinum(IV) (Pt IV ) prodrug amphiphile (ALN-Pt IV -Lipo) covalently bound to alendronate (ALN) and a lipid tail is designed to overcome these limitations. ALN-Pt IV -Lipo can self-assemble into Pt IV lipid nanoparticles (APt IV ) for osteosarcoma targeting chemotherapy and bone destruction inhibition. It is demonstrated that APt IV achieved an eightfold increase in the eradication of osteosarcoma cells compared to cisplatin and threefold selective inhibition of osteosarcoma cells over breast cancer cells via APt IV in vitro. After intravenous injection, APt IV effectively accumulates at the osteosarcoma site in vivo, resulting in significantly suppressed primary osteosarcoma growth, and alleviation of bone destruction. Therefore, APt IV delivers a promising solution for enhanced chemotherapy targeting and bone destruction inhibition in osteosarcoma.
(© 2023 Wiley-VCH GmbH.)
Databáze: MEDLINE
Externí odkaz: